- Home
- BIOT vs MBRX Comparison
BIOT vs MBRX Comparison
Compare BIOT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIOT | MBRX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BIOT | MBRX |
|---|---|---|
| Price | $0.18 | $7.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $240.00 |
| AVG Volume (30 Days) | ★ 429.1K | 280.9K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.16 |
| 52 Week High | $50.00 | $12.65 |
Technical Indicators
Market Signals| Indicator | BIOT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 11.31 | 79.95 |
| Support Level | $0.17 | $2.12 |
| Resistance Level | $0.50 | N/A |
| Average True Range (ATR) | 0.03 | 0.81 |
| MACD | 0.03 | 0.52 |
| Stochastic Oscillator | 6.65 | 79.44 |
Price Performance
Historical ComparisonAbout BIOT Instinct Bio Technical Company Holdings Inc. Ordinary Shares
Instinct Bio Technical Company Holdings Inc is a Cayman Islands-based vertically integrated group engaged in the research and development, manufacturing, branding, and distribution of stem cells, regenerative medicine, wellness, and beauty as its core areas. Its product portfolio includes stem cell-derived serums and skincare formulations for aesthetic and dermatological applications. The company also develops regenerative products for skin healing, hydration, and elasticity.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.